Navigation Links
AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
Date:5/8/2012

REDWOOD CITY, Calif., May 8, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the first quarter ended March 31, 2012.

Net loss for the first quarter of 2012 was $7.1 million, or $0.36 per share, compared with a net loss of $3.2 million, or $0.30 per share, for the first quarter of 2011.  Common shares used in calculating basic and diluted earnings per share were 19,607,483 for the first quarter of 2012 compared to 10,742,182 common shares for the first quarter of 2011.

During the first quarter of 2012, AcelRx recognized revenue of $329,000 resulting from reimbursement for work completed under a research grant from the US Army Medical Research and Material Command, or USAMRMC, for development of its ARX-04 product candidate, a Sufentanil NanoTab® for the treatment of moderate-to-severe acute pain. 

Research and development expenses for the quarter ended March 31, 2012 totaled $4.8 million, compared with $1.9 million for the quarter ended March 31, 2011.  The increase was primarily due to development expenses for ARX-01, the Sufentanil NanoTab PCA System, AcelRx's lead product candidate for the treatment of post-operative pain.  During the first quarter, AcelRx prepared for and initiated the first of three planned Phase 3 clinical trials, a randomized, double-blind, placebo-controlled efficacy and safety trial in adults with post-operative pain, following open-abdominal surgery.  In April 2012, AcelRx initiated the second ARX-01 Phase 3 study, a randomized, open-label, parallel-group comparison of the efficacy and safety of the Sufentanil NanoTab PCA System to the standard of care, IV PCA with morphine, in t
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "China Orthopedic Instrument Industry Report, 2014-2017" ... accelerated aging population and rising proportion of reimbursement for ... been effectively released, with its scale presenting a CAGR ... joint products are three product segments of orthopedic instruments ...
(Date:8/29/2014)... Research and Markets  has announced the addition ... report to their offering. The Central ... the largest segments of pharmaceuticals industry. The numbers of CNS ... therapies were unable to meet the market requirements. There has ... disorder, especially over the past two decades. The market for ...
(Date:8/29/2014)... -- Does your doctor know what you,re smoking?  Chances are, ... to the over 112,000 currently registered patients under ... other roughly 20,300+ active physicians listed with the Colorado Dept ... even though a poll in February 2014 showed 51% of ... it. "With marijuana legalization underway, every doctor ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... , EMERYVILLE, Calif., Nov. 5 Bionovo, Inc. (Nasdaq: ... focused on the unmet needs in women,s health and ... for the three months ended September 30, 2009. , ... 2009, Bionovo successfully completed a public offering and issued ...
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be ... Phoenix, Arizona on Wednesday, November 11, 2009 at 10:00 a.m. ... president of finance and chief financial officer at Amylin Pharmaceuticals, ... of the presentation will be webcast and a recording will ...
Cached Medicine Technology:Bionovo Announces Third Quarter 2009 Highlights and Financial Results 2Bionovo Announces Third Quarter 2009 Highlights and Financial Results 3Bionovo Announces Third Quarter 2009 Highlights and Financial Results 4Bionovo Announces Third Quarter 2009 Highlights and Financial Results 5Bionovo Announces Third Quarter 2009 Highlights and Financial Results 6Bionovo Announces Third Quarter 2009 Highlights and Financial Results 7Bionovo Announces Third Quarter 2009 Highlights and Financial Results 8Bionovo Announces Third Quarter 2009 Highlights and Financial Results 9
(Date:9/1/2014)... Albany, New York (PRWEB) September 01, 2014 ... to store, retrieve, organize and analyze biological and ... comprises of the activity of developing software tools ... is not to be confused with biological computation. ... the better understanding of biology can its related ...
(Date:9/1/2014)... Registration is now open for the 4th Annual ... to be held on Sunday, September 21, 2014. The event ... Meadow in Secaucus, New Jersey. All proceeds from the race ... to restoring a sense of self, restoring the family unit, ... families. , General registration is $30 with special pricing for ...
(Date:9/1/2014)... Daily Gossip reveals in it's review ... that gives members access to thousands of professionally designed ... resource aims to help both people who plan on ... are looking for inspiration in creating one of a ... Now by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 ...
(Date:9/1/2014)... September 01, 2014 Pastor Thompson is an ... at Eagle Village. He is a licensed minister through the ... the past twenty years in New Mexico, Colorado and North ... of marriage this year. He also has two beautiful ... B.S. in Pastoral Ministry from Nazarene Bible College, in Colorado ...
(Date:9/1/2014)... 01, 2014 Psychogenic Non-epileptic Seizures (PNES), ... psychological disorder that can have devastating effects on those ... epileptic seizures however, they are not produced by electrical ... It is estimated that the numbers of persons ... multiple sclerosis. , Dr. Lorna Myers, Director ...
Breaking Medicine News(10 mins):Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2
... key part of health care reform that requires all Americans ... people gaining coverage, but would not dramatically increase the cost ... comes as the U.S. Supreme Court prepares to hear arguments ... key provision of 2010,s Affordable Care Act. According ...
... News) -- Using an autoinjector device to deliver ... effective way to treat status epilepticus, a prolonged type ... report. "This is a very important study for ... French, first vice president of the American Epilepsy Society. ...
... , WEDNESDAY, Feb. 15 (HealthDay News) -- How fast you ... help predict your odds for dementia or stroke later in life, ... can be easily performed in a doctor,s office, noted study author ... and her colleagues tested the walking speed, hand grip strength and ...
... Hospitalization for underage drinking is common in the United States, ... total cost for these hospitalizations is about $755 million per ... found geographic and demographic differences in the incidence of alcohol-related ... Journal of Adolescent Health . Of the ...
... may be receiving the highest exposure to nanoparticles of titanium ... than adults, according to a new study. Published in ACS, ... first broadly based information on amounts of the nanomaterial ... and environmental effects in a wide range of consumer ...
... -- About 27 million Americans aged 50 and older have ... hearing aid, a new study finds. However, many people ... insurance, they don,t receive training in integrating hearing aids into ... part of aging and not a major concern, according to ...
Cached Medicine News:Health News:Ending individual mandate would not dramatically hike insurance prices, study finds 2Health News:Ending individual mandate would not dramatically hike insurance prices, study finds 3Health News:'Autoinjector' Offers Safe, Speedy Care for Life-Threatening Seizures: Study 2Health News:'Autoinjector' Offers Safe, Speedy Care for Life-Threatening Seizures: Study 3Health News:Can Walking Speed, Hand Grip in Middle Age Predict Dementia Risk? 2Health News:Mayo Clinic: Hospitalization of US underage drinkers common, costs $755 million a year 2Health News:Millions of Americans Have Untreated Hearing Loss: Study 2
Large: 22 x 25 mm, 0.9 x 1.0 inches. With holes. For support of the orbital rim following enucleation. Available in methylmethacrylate....
Soft, autoclavable, and without conformer....
Size: Small. 20.50 mm by 22.00 mm. Clear lucite. Supplied sterile....
... x 100 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
Medicine Products: